In September of this year, Gain Therapeutics released positive topline data in a patient-iPSC study done evaluating the companies STAR compounds for the treatment of Parkinson’s disease. The study done in the lab of Professor Ricardo Feldman at the University of Maryland School of Medicine, showed very promising results including the potential for the reversal of neurodegeneration. The topline data was released in a company press release which can be read here.
At the virtual webinar Gain Therapeutics will be releasing the full dataset along with some additional data. Marco Baptista PhD, Vice President of Research Programs at MJFF, said “these encouraging results show promise for this approach to correct dysfunction in the GBA1 pathway, a leading target for Parkinson’s drug development.” Presenting the full dataset at this webinar is a great opportunity for the company to not only update the biopharmaceutical community on the progress being made in the program, but also to potentially form a partnership with a company as Gain looks to move the program into clinical studies.